Onivyde (nal-IRI) is a liposomal irinotecan product indicated for metastatic pancreatic cancer. Clinical trials have demonstrated its efficacy in improving overall survival and progression-free survival when used in combination with other chemotherapies.
How effective is Onivyde in treating pancreatic cancer?
In a Phase 3 trial, the combination of Onivyde with a fluoropyrimidine-based chemotherapy regimen significantly improved overall survival compared to the fluoropyrimidine regimen alone [1]. The study found that patients receiving Onivyde experienced a median overall survival of 6.1 months, compared to 4.2 months for those who did not receive Onivyde [1]. Progression-free survival was also improved in the Onivyde arm [1].
What is the recommended dosage and administration for Onivyde?
Onivyde is administered intravenously. The recommended dose is 80 mg/m² once every two weeks, in combination with a fluoropyrimidine-based chemotherapy regimen [1]. The specific administration details are part of a physician-prescribed treatment plan.
What are the common side effects associated with Onivyde?
The most common adverse reactions reported in clinical trials for Onivyde include diarrhea, fatigue, nausea, vomiting, decreased appetite, and stomatitis [1]. Other potential side effects can include neutropenia, thrombocytopenia, and anemia [1].
How does Onivyde work to treat cancer?
Onivyde is a liposomal formulation of irinotecan, a topoisomerase I inhibitor. The liposomal encapsulation allows for a sustained release of irinotecan, which may help to prolong its exposure in the tumor microenvironment and potentially enhance its antitumor activity [1]. Irinotecan and its active metabolite SN-38 inhibit DNA topoisomerase I, an enzyme essential for DNA replication and repair, leading to DNA damage and cell death in rapidly dividing cancer cells [1].
What is the patent status of Onivyde?
The patent landscape for Onivyde and its associated technologies is complex, with various patents covering the drug formulation, manufacturing, and methods of use. DrugPatentWatch.com provides detailed information on patent expirations and exclusivities for pharmaceutical products, including Onivyde [2].
Are there alternative treatments for metastatic pancreatic cancer?
Several other treatment options exist for metastatic pancreatic cancer, depending on the patient's specific situation and prior treatments. These can include other chemotherapy regimens, targeted therapies, and immunotherapies [3]. The choice of treatment is determined by a medical oncologist based on factors such as disease stage, genetic mutations, and patient health [3].
What clinical trials are ongoing for Onivyde?
Ongoing clinical trials continue to explore the efficacy and safety of Onivyde in various settings and in combination with other agents for pancreatic cancer and potentially other solid tumors. Information on active clinical trials can be found through resources like clinicaltrials.gov.
---
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.cancer.org/cancer/types/pancreatic-cancer/treatment.html